Ameritas Investment Company’s ImmunityBio IBRX Stock Holding History

Ameritas Investment Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-95	Closed	–	–	1373
2018 Q4	$0	Buy	+95	New	+$217	﹤0.01%	1542

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ameritas Investment Company's IBRX Position: Q1 2019 in Review

Ameritas Investment Company sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 95 shares.

Ameritas Investment Company first reported a position in IBRX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

Ameritas Investment Company reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
Ameritas Investment Company sold 95 ImmunityBio shares in Q1 2019.
Ameritas Investment Company first reported a position in ImmunityBio in Q4 2018 and held it in 1 quarter.
Ameritas Investment Company's ImmunityBio position peaked at $0 in Q4 2018.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.